middle.news
Rhythm Biosciences Reports $5.93m Loss Amid First Commercial Sales
5:04pm on Thursday 27th of August, 2026 AEST
•
Healthcare
Read Story
Rhythm Biosciences Reports $5.93m Loss Amid First Commercial Sales
5:04pm on Thursday 27th of August, 2026 AEST
Key Points
Loss after tax increased 55% to $5.93 million
First commercial sales of ColoSTAT® and geneType™ achieved
NHS England commenced evaluation of ColoSTAT®
Cash reserves rose to $3.36 million supported by capital raises
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Rhythm Biosciences (ASX:RHY)
OPEN ARTICLE